Myelodysplastic Syndromes

Overview

Journal West J Med

Specialty General Medicine

Date 1989 Aug 1

PMID 2672599

Citations 6

Authors

D C Doll

A F List

Affiliations

Soon will be listed here.

Abstract

The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic and ineffective hematopoiesis and a varying risk of transformation to acute leukemia. Although the natural history of these syndromes is variable, several factors appear to be of prognostic importance, including the French-American-British classification, the karyotype, in vitro colony formation, and others. The pathogenesis of the myelodysplastic syndrome is not known, but recent evidence suggests that alterations of cellular oncogenes may be a causative factor. There is no standard therapy for myelodysplasia, and thus novel approaches to patient management are warranted.

Citing Articles

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells and .

Arruda L, Stikvoort A, Lambert M, Jin L, Rivera L, Alves R Haematologica. 2022; 107(8):1786-1795.

PMID: 35142149 PMC: 9335119. DOI: 10.3324/haematol.2021.279486.

Hemorrhagic manifestation in different etiologies of pancytopenia: A prospective, cross-sectional study.

Singh M, Singh V, Singh D, Bohra G, Misra A J Family Med Prim Care. 2021; 10(2):804-808.

PMID: 34041080 PMC: 8138370. DOI: 10.4103/jfmpc.jfmpc_1117_20.

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Escalante C, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E Cancer Med. 2019; 8(2):543-553.

PMID: 30632713 PMC: 6382725. DOI: 10.1002/cam4.1953.

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients.

Aznab M, Kavianymoghadam K Int J Hematol Oncol Stem Cell Res. 2014; 7(2):30-4.

PMID: 24505525 PMC: 3913137.

Thrombocytopenia in patients with myelodysplastic syndromes.

Bryan J, Jabbour E, Prescott H, Kantarjian H Semin Hematol. 2010; 47(3):274-80.

PMID: 20620439 PMC: 4428284. DOI: 10.1053/j.seminhematol.2010.02.006.

References

Yunis J, RYDELL R, Oken M, Arnesen M, Mayer M, Lobell M . Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood. 1986; 67(6):1721-30. View

Jacobs R, Cornbleet M, Vardiman J, Larson R, Le Beau M, Rowley J . Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986; 67(6):1765-72. View

Donahue R, Wang E, Stone D, Kamen R, Wong G, Sehgal P . Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature. 1986; 321(6073):872-5. DOI: 10.1038/321872a0. View

Tricot G, Boogaerts M . The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol. 1986; 63(3):477-83. DOI: 10.1111/j.1365-2141.1986.tb07524.x. View

Tricot G, Mecucci C, Van Den Berghe H . Evolution of the myelodysplastic syndromes. Br J Haematol. 1986; 63(4):609-14. DOI: 10.1111/j.1365-2141.1986.tb07544.x. View

Kuriyama K, Tomonaga M, Matsuo T, Ginnai I, Ichimaru M . Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986; 63(4):665-9. DOI: 10.1111/j.1365-2141.1986.tb07550.x. View

Cheson B, Jasperse D, Simon R, Friedman M . A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986; 4(12):1857-64. DOI: 10.1200/JCO.1986.4.12.1857. View

Hemmi H, BREITMAN T . Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood. 1987; 69(2):501-7. View

Kere J, Ruutu T, de la Chapelle A . Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome. N Engl J Med. 1987; 316(9):499-503. DOI: 10.1056/NEJM198702263160902. View

10.

Trinchieri G, Rosen M, Perussia B . Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocytic leukemic cell line HL-60. Blood. 1987; 69(4):1218-24. View

11.

Clark R, Jacobs A, Lush C, Smith S . Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet. 1987; 1(8536):763-5. DOI: 10.1016/s0140-6736(87)92796-6. View

12.

Levine E, Bloomfield C . Secondary myelodysplastic syndromes and leukaemias. Clin Haematol. 1986; 15(4):1037-80. View

13.

Nowell P . Cytogenetics of preleukemia. Cancer Genet Cytogenet. 1982; 5(3):265-78. DOI: 10.1016/0165-4608(82)90034-6. View

14.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-99. View

15.

Greenberg P . The smoldering myeloid leukemic states: clinical and biologic features. Blood. 1983; 61(6):1035-44. View

16.

Bynoe A, Scott C, Ford P, Roberts B . Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol. 1983; 54(1):97-102. DOI: 10.1111/j.1365-2141.1983.tb02071.x. View

17.

Raskind W, Tirumali N, Jacobson R, Singer J, Fialkow P . Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. 1984; 63(6):1318-23. View

18.

Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen R . Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol. 1984; 57(3):423-30. DOI: 10.1111/j.1365-2141.1984.tb02916.x. View

19.

Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen R . Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984; 58(2):217-25. DOI: 10.1111/j.1365-2141.1984.tb06079.x. View

20.

Tricot G, De Bock R, Dekker A, Boogaerts M, Peetermans M, PUNT K . Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br J Haematol. 1984; 58(2):231-40. DOI: 10.1111/j.1365-2141.1984.tb06081.x. View